Cbe, ma (Oxon), mbchB, bsc (Hons), msc, PhD, md, dsc, frcp (Glasgow,Edinburgh and London), frcgp (hon), fcanSci, fmedSci

Download 443.19 Kb.

Page	7/11
Date	13.06.2017
Size	443.19 Kb.
	#20763

1 2 3 4 5 6 7 8 9 10 11

PEER REVIEWED PUBLICATIONS

PUBLICATIONS

PUBLISHED ABSTRACTS

Over 300 Abstracts presented at national and international conferences.

THESES

BSc: Degradation of the neuropeptide, metenkephalin by human plasma

MSc The clinical pharmacology of LM985 - an experimental cytotoxic drug
MD Aspects of cytotoxic drug penetration
PhD Regulation of proliferation of breast cancer cells by growth factors.
DSc The Molecular pharmacology of anticancer therapy

PEER REVIEWED PUBLICATIONS

In 4 sections: Colorectal Cancer; Drug Development; Gene Therapy; General Medicine

Section 1: Colorectal Cancer

Huijbers A, Tollenaar RAEM, Pelt GWV, Zeestraten ECM, Dutton S, McConkey CC, Domingo E, Smit VTHBM, Midgley R, Warren BF and Kerr DJ

The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the victor trial
Annals of Oncology 24(1):179-185 2013
Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley R, Kerr D, Sieber O, Tomlinson IUse of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 229(3):441-448 Feb 2013
Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Almeida EG, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphray S, The CORGI Consortium, Thomas HJ, Maher E, Evans G, Lucassen A, Cummings C, Stevens M, Walker L, Halliday D, Armstrong R, Paterson J, Hodgson S, Homfray T, Side L, Izatt L, Donaldson A, Tomkins S, Morrison P, Goodman S, Brewer C, Henderson A, Davidson R, Murday V, Cook J, Haites N, Bishop T, Sheridan E, Green A, Marks C, Carpenter S, Broughton M, Greenhalge L, Suri M, The WGS500 Consortium, Steering Committee:, Donnelly P, Bell J, Bentley D, McVean G, Ratcliffe P, Taylor J, Wilkie A, Operations Committee:, Donnelly P, Broxholme J, Buck D, Cazier JB, Cornall R, Gregory L, Knight J, Lunter G, McVean G, Taylor J, Tomlinson I, Wilkie A, Sequencing & Experimental Follow-up:, Buck D, Gregory L, Humphray S, Kingsbury Z, Data Analysis:, McVean G, Donnelly P, Cazier JB, Broxholme J, Grocock R, Hatton E, Holmes CC, Hughes L, Humburg P, Kanapin A, Lunter G, Murray L, Rimmer A, Lucassen A, Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ, McVean G, Houlston RS, Tomlinson I Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
Nat Genet 45(2):136-144 23 Dec 2012
Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, Kerr D, Oukrif D, Novelli M, Abulafi M, Hodgson SV, Fadhil W, Ilyas M, Tomlinson IP Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.
Oncotarget 3(11):1348-1355 Nov 2012
Schmoll HJ, Van cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, Van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El ghazaly H, Gallardo J, Garin A, Glynne-jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A Esmo consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Annals of Oncology 23(10):2479-2516 2012
Kennedy RH, Francis A, Dutton S, Love S, Pearson S, Blazeby JM, Quirke P, Franks PJ, Kerr DJ

EnROL: A multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme

BMC Cancer 12 2012
Kinnersley B, Migliorini G, Broderick P, Whiffin N, Dobbins SE, Casey G, Hopper J, Sieber O, Lipton L, Kerr DJ, Dunlop MG, Tomlinson IP, Houlston RS The TERT variant rs2736100 is associated with colorectal cancer risk
British Journal of Cancer 107(6):1001-1008 2012

La Thangue, NB and Kerr DJ. Predictive biomarkers: a shift towards personalised cancer medicine Nature Reviews Clinical Oncology 8, 587-596,.2011

Kerr,DJ and Young AM. Targeted therapies:Bevacizumab – has it reached its final resting place? Nature Reviews Clinical Oncology 8, 195-196 , 2011

J Hecht, T Trarbach, J Hainsworth, P Major, E Jager, R Wolff, K Lloyd-Salvant, G Bodoky, K Pendergrass, W Berg, B Chen, T Jalava, G Meinhardt, D Laurent, D Lebwohl, and D Kerr. A Randomized, Placebo-Controlled, Phase III Study of First-line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584 (Vatalanib), an Oral VEGF Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma J Clin Oncol, 2011:1997-2003

Niedzwiecki D, Bertagnolli M, Warren S, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts SR, Porjosh GN , Kerr DJ, Fields, Goldberg< Mayer R, Colaccio TA Documenting the natural historyof patients with resection of stage2 adenocarcinoma of the colon after randomisation to Edrocolomab or observation. . J Clin Oncol , 11, 2011:3146-3152
Quirke P, Hutchins G, Southward K, Hardley K, Magill L, Beaumont C, Stahlschmidt J, Rickman S, Chambers P, Seymour M, Gray R and Kerr DJ. Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol, 2011:1261-1270
Salazar R, Roepman P, Capella G, Moreno V, Simon I, López-Doriga1 A, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, M Glas A, Van ’t Veer L and Tollenaar R. A Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer J Clin Oncol, 1,2011:17-24
Gray R, Quirke P, Hardley K, Lopatin M, Magill L, aehner FL, Beaumont C, Clark-Langore KM, Yoshiwarza CN, Lee M, Watson D, Shak S and Kerr DJ. Validation Study of a Quantitative multi-gene RT-PCR assay as a predictor of recurrence in stage II colon cancer patient. J Clin Oncol, 12,2011:4611-4619
Houlston R, Cheadle J, Dobbins S, et al. Meta-analysis of three UK genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 42,973-77,2010.

Chen l, Zeng X, Wang J, Briggs SS, O’Neil E, Li J, Leek R, Kerr DJ, Harris AL, Cai L . Roles of Tetrahydrobiopterin in promoting tumour angiogenesis. Am J Pathol 2010 , 179: 2671-2680

Midgley RS, McConkey C, Kerr DJ et al. Final Results of the VICTOR Trial: A Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer. J Clin Oncol, 4575-4580, 2010.
Kerr DK and Midgley R. Defective Mismatch Repair in Colon Cancer: A prognostic or predictive biomarker? – Journal of Clinical Oncology, 3210-3212, 2010
The International Cancer Genome Consortium. Sequencing the cancer genome. Nature 2010 Apr 15;464(7291):993-8.
Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Letters 286 (2009) 114–120
Al-Salama H, Johnstone E and Kerr DJ. What Is the Role and Impact of Molecular Markers on Treatment Decisions for Colorectal Cancer in the Adjuvant Setting? Discovery Medicine. 2009. Discovery Medicine, volume 8, number 42, Pages 104-107.
Kerr DJ and Kakil IR. Targeted therapies: Cetuximab plus chemotherapy in patients with advanced cancer. Nature Reviews Clinical Oncology. 2009 Sep;6(9):499-500
Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr DJ. Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer, 2009, 9: 489-499.
Luis S, Spain S, Tomlinson I, Kerr D; Houlston R, Cazier J. Common variation at the Adiponectin locus is not associated with colorectal cancer risk in the United Kingdom. Human Molecular Genetics, 18, 1889-1892, 2008.
Midgley RS, Yanagisawa Y, Kerr DJ. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):108-20.
Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, De Gramont A, for the Adjuvant Colon Cancer Endpoints (ACCENT) Group16. Evidence for cure by adjuvant therapy in colon cancer: Observations Based on Individual Patient Data from 20,898 Patients of 18 Randomized Trials. : J Clin Oncol. 2009 Feb 20;27(6):872-7.
Midgley R, Kerr DJ. Capecitabine: have we got the right dose? Nature Clinical Practice. Vol 6: 1, 17-24. Oct 2008.
Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven N, Kerr DJ, Young LS, Adams DH. 3A Phase II Study of Adoptive Immunotherapy Using Dendritic Cells Pulsed with Tumor Lysate in Patients with Hepatocellular Carcinoma. Hepatology. 2009 Jan;49(1):124-32.

Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Raffaele Bianco A, El-Serafi M, Bedenne L, Paillot B, Minik, Evaristo E. Raltitrexed (Tomudex_) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). 2008. European Journal of Cancer, 44, 2004-2211.

Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset J-F, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier R, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van De Velde C, Zalcberg J. The diagnosis and management of rectal cancer. Expert discussion and recommendations derived from the 9^th world congress on gastrointestinal cancer, Barcelona, 2007. Annals of Oncology. 19 (supplement 6): vii1-vi8, 2008

Kerr DJ. Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment. Nature Clinical Practice Oncology. Vol 5, 250-251.2008

Cogent Study Group Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genetics 40, 1426-35,2008

Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman A, Spain S , Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington S, Tenesa A, Prendergast J, Barnetson R, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop T, Gray R, Maher E, Lucassen A, Kerr D, Evans E, The CORGI Consortium, Schafmayer C, Buch S, Izke H, Hampe J, Schreiber S, John U, Koessler T, Pharoah P, van Wezel T, Morreau H, Wijnen J, Hopper J, Southey M, Giles G, Severi G, Castellvı´-Bel S, Ruiz-Ponte C, Carracedo A, Castells A, The EPICOLON Consortium, Fo¨rsti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, WC Ho J, Cheng K, Sham P, Luk J, Agu´ ndez J , Ladero J, de la Hoya M, Calde´s T, Niittyma¨ki I, Tuupanene S, Karhu A, Aaltonen L, CazierJB, Campbell H, Dunlop M, & Houlston R. A genome-wide association study identifies novel colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics.

40, 623-630. 2008.

Jaeger E, Webb E, Howart K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittma A, Kemp Z, Sullivan K, Heinimann K, Lubbe, Domingo E, Barclay E, Martin L, Gorman M, Chandler I, Vijayakrishna J, Wood, Papaemmanuil E, Penegar S, Qureshi M, members of the CORGI consortium, Tenesa A, Cazier JB, Kerr D, Gray R, Peto P, Dunlop M, Thomas HH, Houlston R, Tomlinson I. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nature Genetics, 40: 26-28, 2007.

Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z, Gorman M, Chandler I, Papaemmanuil E, Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Kerr D, Gray R, Peto J, Cazier JP, Tomlinson I, Houlston R. A genome-wide association study shows that common alleles of : SMAD7: influence colorectal cancer risk. Nature Genetics 39, 1315 - 1317 (14 Oct 2007).

Sabharwal A and Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Review Anticancer Therapy. 7 (4), 477-487, 2007.

Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll H, Tabernero J, Tempero M, Van De Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8^th world congress on gastrointestinal cancer, Barcelona, 2006. Annals of Oncology. 18 (supplement 7): vii1-vii10, 2007.
Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Francois Seitz J, O'callaghan CJ, Francini G, Grothey A, O'connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, Gramont AD. End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. J Clin Oncol. 29: 4569-4574, 2007.
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, Cazier JB, Houlston R. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics 39, 984-988 (01 Aug 07)
Kerr DJ, Dunn JA, Langman MD, Smith JL, Midgley RJ, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC. Rofecoxib and Cardiovascular adverse events in adjuvant treatment of colorectal cancer. New England Journal of Medicine, 357:360-9. July 2007
Gray, R, Barnwell J, McConkey C, Williams N and Kerr, DJ. QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative Group. Lancet, 370(9604):2020-9. 2007

Kerr David J. Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis? Nature Clinical Practice Oncology 3, 480 – 481. 2006.

Shimizu, Maruta F, Akita N, Miwa S, Seymour L, Kerr, D, Parker A, Miyagawa S. Identification of an oligopeptide binding to Hepatocellular carcinoma. Oncology 941. 2006
Russo, A, Bazan V, Iacopetta B, Kerr, D, Sonssi T, Gebbia N. The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumour Site, Type of Mutation, and Adjuvant Treatment. Journal of Clinical Oncology. 23: 2005, 7518-7528.
Sargent DJ, Wieand HS, Haller D G, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point of adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomised trials. Journal of Clinical Oncology. 2005, 23, No 34: pp. 8664-8670
Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol. 2005 Jul;16(7):1123-32. Epub 2005 Jun 6.
Neoptolemos J. P., Stocken D. D., Friess H., Bassi C., Dunn J. A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D. J., Büchler M. W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New England Journal of Medicine. 350; 12. March 2004.
Chan, R and Kerr DJ. Can we individualise chemotherapy for colorectal cancer? Annals of Oncology. 15, 996-999, July 2004
Kerr D and Van Cutsem E. New approaches for the treatment of colorectal cancer in the adjuvant setting. Eur J Cancer. Vol 2 No 7, 34-39. 2004
Grabsch H, Kerr D and Quirke P. Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours?. Histopathology. 45, 312-334. 2004
Kerr D. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature Clinical Practice, Oncology. Vol 1, 39-43, 2004
Kerr DJ. Clinical development of gene therapy for colorectal cancer. Nature Reviews Cancer, (2003) 3 615-622.
Grumett, SA and Kerr DJ. Irinotecan and Capecitabine in a patient with advanced colorectal cancer. Case Studies in Colorectal Cancer. (August 2003), Vol2, No.5.
Nicum S, Midgley R, Kerr DJ. Colorectal cancer. Acta Oncol. 2003;42(4):263-75.
Kerr, D.J., McArdle, C.S; Ledermann, J; Taylor, I; Sherlock, S.J; Schlag, P.M; Buckels, J; Mayer, D; Cain, D; Stephens, R.J. Intrahepatic arterial versus intravenous 5 fluorouracil and leucovorin for colorectal cancer liver metastases: results of a multicentre randomised trial, Lancet, 2003, 361,368-373

Midgley, RS; Kerr, D.J. Immunotherapy for colorectal cancer. Expert Rev. Anticancer Ther. 3(1), 63-78, 2003.

Maughan TS, James RD, Kerr D, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ on behalf of the MRC Colorectal Cancer Group Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal: a multicentre randomized trial. Lancet, 2003;361:457-64

Download 443.19 Kb.

Share with your friends:

1 2 3 4 5 6 7 8 9 10 11